Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 7/20 | 0.59 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.50 |
| ▸ | ADK | P55263 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12803573 | 1.00 | SLC29A1 (0.59) | SLC29A1PAX8ADORA1ADKCYP1A2 | |
| SCHEMBL2221717 | 0.90 | ADORA2A (0.60) | SLC29A1PAX8ADORA1ADORA2AADORA3 | |
| SCHEMBL2221710 | 0.90 | ADORA2A (0.60) | SLC29A1PAX8ADORA1ADORA2AADORA3 | |
| SCHEMBL2220567 | 0.87 | SLC29A1 (0.65) | SLC29A1ADORA1CYP1A2ADORA2AADORA3 | |
| SCHEMBL2220562 | 0.87 | SLC29A1 (0.65) | SLC29A1ADORA1CYP1A2ADORA2AADORA3 | |
| SCHEMBL2221601 | 0.86 | SLC29A1 (0.52) | SLC29A1PAX8ADORA1ADKCYP1A2 | |
| SCHEMBL2221596 | 0.86 | SLC29A1 (0.52) | SLC29A1PAX8ADORA1ADKCYP1A2 | |
| SCHEMBL2342723 | 0.85 | SLC29A1 (0.48) | SLC29A1PAX8ADORA1CYP1A2ADORA2A | |
| SCHEMBL31343011 | 0.85 | SLC29A1 (0.62) | SLC29A1PAX8ADORA1 | |
| SCHEMBL2342716 | 0.85 | SLC29A1 (0.48) | SLC29A1PAX8ADORA1CYP1A2ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877439-B2 | Method for rapidly evaluating performance of short interfering RNA with novel chemical modifications | SIRNA THERAPEUTICS, INC. (US) | 2014-11-04 | — | — | US | claimed |
| US-9512426-B2 | Method for rapidly evaluating performance of short interfering RNA with novel chemical modifications | SIRNA THERAPEUTICS, INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-20150132761-A1 | METHOD FOR RAPIDLY EVALUATING PERFORMANCE OF SHORT INTERFERING RNA WITH NOVEL CHEMICAL MODIFICATIONS | BANK OF AMERICA, N.A. | 2015-05-14 | — | — | US | disclosed |
| US-8877439-B2 | Method for rapidly evaluating performance of short interfering RNA with novel chemical modifications | SIRNA THERAPEUTICS, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-20120252027-A1 | Method For Rapidly Evaluating Performance Of Short Interfering RNA With Novel Chemical Modifications | BANK OF AMERICA, N.A. | 2012-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252027-A1 | Method For Rapidly Evaluating Performance Of Short Interfering RNA With Novel Chemical Modifications | NSUN2, NSUN3, SNRPE | SLC29A1 514/4885PAX8 4474/4885ADORA1 1080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.